EP Patent

EP1143940A2 — Compositions and methods for mucosal delivery

Assigned to Lavipharm Laboratories Inc · Expires 2001-10-17 · 25y expired

What this patent protects

A dosage unit comprising a water-soluble hydrocolloid and a mucosal surface-coat-forming, such film including an effective dose of active agent. In the dosage unit slidenafil citrate, nicotine, hydromorphone, oxybutynine or estradiol are used as active agents.

USPTO Abstract

A dosage unit comprising a water-soluble hydrocolloid and a mucosal surface-coat-forming, such film including an effective dose of active agent. In the dosage unit slidenafil citrate, nicotine, hydromorphone, oxybutynine or estradiol are used as active agents.

Drugs covered by this patent

apomorphine-hydrochloride (APOMORPHINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP1143940A2
Jurisdiction: EP
Classification: —
Expires: 2001-10-17
Drug substance claim: No
Drug product claim: No
Assignee: Lavipharm Laboratories Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.